Titre
Skin blood flow reduction induced by cigarette smoking: role of vasopressin
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
Waeber, B.
Auteure/Auteur
Schaller, M. D.
Auteure/Auteur
Nussberger, J.
Auteure/Auteur
Bussien, J. P.
Auteure/Auteur
Hofbauer, K. G.
Auteure/Auteur
Brunner, H. R.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0363-6135
Statut éditorial
Publié
Date de publication
1984-12
Volume
247
Numéro
6 Pt 2
Première page
H895
Dernière page/numéro d’article
901
Notes
Journal Article Research Support, Non-U.S. Gov't --- Old month value: Dec
Résumé
The effect of vasopressin released by cigarette smoking on blood pressure (BP), heart rate (HR), and skin blood flow (SBF) was investigated in 12 normotensive habitual smokers. At a 1-wk interval, each subject smoked within 10 min two cigarettes before and after intravenous injection of either the specific vascular vasopressin antagonist d(CH2)5Tyr(Me)AVP (5 micrograms/kg) or its vehicle administered in double-blind fashion. SBF was assessed with a laser Doppler flowmeter. Smoking increased plasma vasopressin (P less than 0.01). In six subjects subsequently treated with the antagonist, plasma vasopressin rose to greater than 10 pg/ml and SBF fell by 18.2 +/- 4.8%. This SBF reduction was prevented by the vasopressin antagonist. In contrast, the vehicle had no effect. In the 24 studies taken together, there was a significant correlation (r = -0.60, P less than 0.01) between the SBF decrease during the first smoking period and the plasma vasopressin levels measured afterwards. The BP and HR rise caused by smoking was not modified by the antagonist. Thus it appears that the decrease in SBF induced by smoking is due to enhanced vasopressin secretion.
Sujets
PID Serval
serval:BIB_EE814E5283E7
PMID
Date de création
2008-03-05T15:41:08.195Z
Date de création dans IRIS
2025-05-21T05:28:00Z